CytRx Corp. | Mutual Funds
Mutual Funds that own CytRx Corp.
Vanguard Total Stock Market Index Fund
492,357
1.46%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
261,880
0.78%
2,000
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
105,625
0.31%
0
0%
07/31/2018
iShares Micro Cap ETF
70,539
0.21%
0
0.01%
09/06/2018
Fidelity Spartan Total Market Index Fund
40,644
0.12%
0
0%
07/31/2018
Fidelity Nasdaq Composite Index
40,315
0.12%
0
0%
07/31/2018
Vanguard Balanced Index Fund
21,911
0.07%
0
0%
07/31/2018
Vanguard Institutional Total Stock Market Index Fund
19,563
0.06%
0
0%
07/31/2018
8,616
0.03%
0
0.03%
09/05/2018
BlackRock Master Extended Market Index Series
7,637
0.02%
0
0%
01/31/2018
| Address |
11726 San Vicente Boulevard
Los Angeles California 90049
United States
|
|
Employees
|
- |
| Website |
http://www.cytrx.com |
| Updated |
07/08/2019 |
| CytRx Corp. operates as a biopharmaceutical research and development company specializing in oncology. It focuses on discovering, developing, and commercializing new therapeutics to treat patients with cancer; including aldoxorubicin, a modified version of the widely-used chemotherapeutic agent, doxorubicin. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA. |
